Skyhawk Therapeutics’ Post

Don't forget to register your attendance to the FREE Webinar with MarketOpen Australia that is being held tomorrow, Wednesday 24th July over Zoom. Dr Liz Dallimore will be providing an update on our Phase 2 clinical trial program. Learn more through the post below ⬇️ #AGN #ASX #stroke #clinicaltrial #strokeawareness #lifescience #investorupdate

At RealizedCare we've always believed that #digitaltherapeutics will improve access, improve health, and drive attendant savings in healthcare - all vital for improving population health and making our healthcare system sustainable. Digital therapeutics are poised to be one of the most transformative shifts in healthcare - shattering barriers of access and affordability. Read Mario Aguilar's insightful article to get a look at how RealizedCare, Freespira and Akili are evolving our business models to unlock the full value of DTx. (and we are just three examples - learn more at Digital Therapeutics Alliance!) Joseph Perekupka, Eddie Martucci, Andy Molnar

“We have to make the thing we’re bringing to market look more like something that the market understands how to value and how to buy. The market doesn’t understand exactly how to buy and deploy digital therapeutics." Our founder and CEO Aaron Gani recently spoke with STAT's Mario Aguilar about the evolution of RealizedCare and how our new digital care management solution for chronic pain aims to solve notable challenges within the digital therapeutics industry. Read more: https://hubs.la/Q02gYDgC0 #ChronicPain #DigitalCareManagement #DigitalHealth #CareManagement #DigitalTherapeutics

Many people have seen the Calm app on T.V., but what do you know about the apps that are actually FDA cleared and require a prescription? Here is a brief review of those apps cleared for use in mental health disorders. #digitalhealth #pharmacy #USCMann

We are thrilled to announce that JEITO has led a €75M Series B financing round for NMD Pharma A/S, a Danish clinical-stage biotech company dedicated to developing innovative treatments for patients living with severe neuromuscular disorders. Following our initial investment in 2022, this second round of funding illustrates our steady support to growing and perfoming NMD Pharma A/S and its ambition to become a leading, global, clinical-stage company. The proceeds will be used to complete three Phase 2 clinical Proof of Concept studies with NMD670, the company's leading CIC-1 inhibitor, which has the potential to restore muscle function in a range of rare neuromuscular diseases, including myasthenia gravis, spinal muscular atrophy, and Charcot Marie Tooth. The funding will also contribute to grow its pipeline and support the expansion of NMD Pharma’s clinical and commercial operations in Denmark and in the US. We are very proud to stand alongside Thomas Holm Pedersen, the CEO, and his team as they embark on this new chapter, driven by their unwavering commitment to making a positive impact on patients. Read more 👉 https://lnkd.in/ev_3hjv8 #FasterForThePatient #privateequity #lifesciences #biopharma #healthcare #neuromusculardisease

🌟 #MerlinMonday Spotlight 🌟 Today, we're shining a light on our oncology-specific supply chain solutions, meticulously tailored to meet the unique demands of oncology clinical trials. 💼💉 Rely on Merlin SCC to optimize drug procurement processes, manage temperature-sensitive logistics with precision, and implement patient-centric supply strategies to enhance patient outcomes. From protocol design to patient recruitment and safety monitoring, our comprehensive support ensures the success of your oncology research. Choose expertise, choose reliability, choose Merlin SCC for your Oncology-Specific Support needs! #OncologySupport #ClinicalTrials #ChooseMerlinSCC #MerlinSCC #HealthcareInnovation #SupplyChainManagement 🌐

Infusion drug cost can make up 85% of an oncology practice’s total expenses. Our new solution (launching in just 10 days!) will keep your infusion suite sustainable, and it fits right in with the rest of our products. Too excited to wait for the big reveal? We can spill the beans now. https://bit.ly/3OQR7Z5 #newsolution #oncologypracticemanagement

Welcome back to 2024! This year is gearing up to be even bigger than 2023 for Argenica Therapeutics, with Phase 2 clinical trial in acute ischaemic stroke (AIS) patients right around the corner. If you missed it, last month we provided a company update that addressed the current status of the clinical trial. ⬇ You can find the announcement here ⬇ AGN investor announcement: https://bit.ly/3NVPdWu #ASX #AGN #investor #clinicaltrial #clinicaltrialupdate #stroke #strokeawareness

Rob Etherington, our CEO, discusses innovation, regulatory, and investor challenges and opportunities in the #raredisease therapeutics market with Mike Ward of Clarivate. “We’ve seen regulatory flexibility start to occur for rare diseases and it is a godsend to the patients. More needs to be done… Rare diseases are important fights that we must continue every day,” says Rob. Tune in to hear Rob’s insights on rare disease therapies as Clene Nanomedicine, Inc. works to #EndALS: https://bit.ly/3VO0HQB

Can treprostinil inhalation solution (nebulized Tyvaso) make significant patient outcome change in IPF patients? When I learned about the United Therapeutic's TETON trial program, I was amazed by the company audacity. IPF and ILDs have become the treatment graveyard and we have seen multiple failures in the past, including Galapagos' ISABELA replicate studies. As we await the outcomes of the TETON studies, the possibility of a breakthrough in the treatment of IPF and ILDs remains a fervent wish, one that could herald a new era in the management of these conditions. United Therapeutics Corporation Announces Full Enrollment of the TETON 2 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis – United Therapeutics Corporation